SNDX-5613
Modify Date: 2024-01-06 16:08:08
SNDX-5613 structure
|
Common Name | SNDX-5613 | ||
|---|---|---|---|---|
| CAS Number | 2169919-21-3 | Molecular Weight | 630.82 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C32H47FN6O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SNDX-5613SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1]. |
| Name | SNDX-5613 |
|---|
| Description | SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1]. |
|---|---|
| Related Catalog | |
| Target |
Menin-MLL[1] |
| In Vivo | SNDX-5613 shows in vivo plasma IC50 of 53 nM. SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1]. |
| References |
| Molecular Formula | C32H47FN6O4S |
|---|---|
| Molecular Weight | 630.82 |
| Storage condition | -20°C |